Toxicity of Eun-bi San Pharmacopuncture Injection in the Muscle of Rats

Jongcheol Lee1,2, Hohyun Jeong1,2, Eunhye Cha1,2, Manyong Park1,2, Sungyoul Choi3, Taehan Yook4, InJa Song5, Sungchul Kim1,2*

1Department of Acupuncture & Moxibustion Medicine, Wonkwang University Gwangju Korean Medical Hospital, Gwangju, Korea
2Nervous & Muscular System Disease Clinical Research Center of Wonkwang University Gwangju Korean Medical Hospital, Gwangju, Korea
3Department of Neuropsychiatry, Wonkwang University Gwangju Korean Medical Hospital, Gwangju, Korea
4Department of Acupuncture & Moxibustion Medicine, Woosuk University Hospital of Korean Medicine, Jeonju, Korea
5Department of nursing Kwang-Ju Women’s University, Gwangju, Korea

Key Words
eun-bi san, pharmacopuncture, toxicity test

Abstract

Objectives: This study was carried out to analyze the single-dose toxicity of Eun-Bi San pharmacopuncture injected into the muscle of Sprague-Dawley (SD) rats.

Methods: All experiments were performed at Biotoxtech, an institution certified to conduct non-clinical studies under the Good Laboratory Practice (GLP) regulations. Six week old SD rats reared by ORIENTBIO were chosen for this pilot study. The reason SD rats were chosen is that they have been widely used in safety tests in the field of medicine, so the results can be easily compared with many other databases. The Eun-Bi San pharmacopuncture was made in a clean room at the Korean Pharmacopuncture Institute (KPI, K-GMP). The constituents of the Eun-Bi San pharmacopuncture are Angelicae gigantis radix, Strychni semen and Glycyrrhizae radix. These were extracted at low temperature and low pressure in an aseptic room at the KPI. Doses of Eun-Bi San pharmacopuncture, 0.25, 0.5 and 1.0 mL, were administered to the experimental groups, and a dose of normal saline solution, 1.0 mL, was administered to the control group. This study was performed under the approval of the Institutional Animal Ethics Committee of Biotoxtech Co., Ltd.

Results: No deaths or abnormalities occurred in any of the four groups. No significant changes in weight, hematological parameters or clinical chemistry between the control group and the experimental groups were observed. To determine if abnormalities existed in any organs and tissues, we used microscopy to examine representative histological sections of each specified organ; the results showed no significant differences in any of the organs or tissues.

Conclusion: The results of this study suggest that treatment with Eun-Bi San pharmacopuncture is relatively safe and that its clinical use may be beneficial. Further evaluations and studies on this subject will be needed to provide more concrete evidence in support of these conclusions.

1. Introduction

Pharmacopuncture is a new form of acupuncture treatment combining acupuncture and herbal medicine. With acupuncture based on the meridian theory and herbal medicine based on Qi and flavor theory, pharmacopuncture utilizes both meridian and Qi/flavor theory. Pharmacopuncture treatment requires differential diagnosis by a traditional Oriental medicine practitioner to select a matching herbal extract, and...
the injections are given at several acupoints to attain benef-
its of both acupuncture and herbal medicine [1]. Thus, a
single procedure, can achieve both the effects of acupunc-
ture and herbal medicine. As the pharmacopuncture does
not pass through the digestive system, it works fast and has
effects that oral administration does not have [2]. For this
reason, pharmacopuncture for herbal medicine has been
widely used.

The constituents of the Eun-Bi San pharmacopuncture are
Angelicae gigantis radix, Strychni semen and Glycyrrhizae
radix. These were extracted at low temperature and low
pressure in an aseptic room at the Korean Pharmacopun-
ture Institute (KPI). Eun-Bi San Pharmacopuncture is
known to be beneficial to pain control and to have an an-
ti-inflammatory effect clinically.

Studies on the toxicities of the components Eun-Bi San
pharmacopuncture have been published. Seo and Roh con-
ducted a philological study on the poisoning and side
effects of Angelicae sinensis radix [3], and Kang conduct-
ed a study on the antimicrobial effect and the cytotoxicity
of Glycyrrhizae radix in vitro [4]. Nevertheless, objective
single-dose toxicity testing of the Eun-Bi San pharmacopun-
ture, which is a complex combination of herbs, has not
been conducted yet. Therefore, this study was performed
to analyze the single-dose toxicity and to determine the le-
thal dose of Eun-Bi San pharmacopuncture in rats.

Studying the acute and the subacute toxicities through
Good Laboratory Practice (GLP) regulations is the current
research trend for single-dose toxicity testing of extracts.
All the experiments for this study were conducted at Bio-
toxtech.

2. Materials and Methods

The Eun-Bi San pharmacopuncture was made in a clean
room at the KPI (K-GMP). After the mixing process with
sterile distilled water, the pH was controlled to between
7.0 and 7.5. Then, NaCl was added to make a 0.9% isotonic
solution by using sterilized equipment. The completed ex-
tract was stored in a refrigerator (2.1 – 5.5°C), until it was
used. The date of manufacture on this extract was 2013-4-
21, and its valid date was 2013-10-21.

In this study, six-week-old Sprague-Dawley (SD) rats
reared by ORIENTBIO were used. The reason SD rats were
chosen is that they have been widely used in safety tests
in the field of medicine, so the results can be easily com-
pared with many other data-bases. The weights of the male
rats ranged from 177.6 to 193.2 g, and those of female rats
ranged from 150.3 to 176.8 g at the time of injection. Upon
import, for all animals, a visual inspection was conducted;
all animals were weighed using a CP32025 system (Sarto-
rius, Germany). During 7 days of acclimatization, the gen-
eral symptoms of the rats were observed once a day. The
weights of the rats were recorded on the last day of accli-
atization. No abnormalities were found.

The temperature of the breeding environment was 21.1 —
22.7°C, the humidity was 44.3% — 56.6%, and the illu-
mination was 150 — 300 Lux. Feedstuff (Teklad Certified
Irradiated Global 18% Protein Rodent Diet 2918C) and UV
filtered water were provided.

After 7 days of acclimatization, animals were selected and
and grouped by using the criteria of their weights being close to
the mean weight. In total, 20 male rats and 20 female rats
were selected. The animals were randomly distributed into
4 groups (5 male and 5 female mice per group), as shown
in Table 1.

Because the usual dose for Eun-Bi San pharmacopunc-
ture is 1.0 mL per treatment in clinical applications, 1.0 mL
of Eun-Bi San pharmacopuncture was injected into each
male and female rat in a pilot test. In this study, 1.0 mL/
normal saline was set as a high dose, and 0.5 mL/animal and 0.25
mL/animal were set as the mid dose and the low doses,
respectively. In the control group, 1.0 mL of normal saline
solution was administered. Disposable syringes were used
to inject a single dose, 0.25 and 0.5 mL/animal, of Eun-Bi
San pharmacopuncture into the left thigh muscle of the
rats in the low dose and the mid dose groups, respectively.
0.5 mL of Eun-Bi San pharmacopuncture was injected into
each thigh muscle of the rats in the high dose group, for
a total of 1.0 mL/animal. This study was performed under
the approval of the Institutional Animal Ethics Committee
of Biotoxtech Co., Ltd.

The general symptoms were observed once a day from
the 1st day to 14th day after treatment. On the administra-
tion day (day 0), the general symptoms (kinds of side ef-
effects, revealing time, recovery time, etc.), as well as mortal-
ity, were examined at 30 minutes and at 1, 2, 4, and 6 hours
after injection. The weights were measured immediately
before treatment and at 3, 7 and 14 days after treatment.

After fasting for more than 18 hours before autopsy, the
rats were anesthetized by using isoflurane. Blood samples
were taken from the abdominal aorta on the day of autopsy

| Group         | Eun-Bi San Injection (mL/animal) | Number of animals (serial numbers) |
|--------------|---------------------------------|------------------------------------|
|              |                                 | Male                               | Female                            |
| G1: Control group | 0                               | 5 (1101 - 1105)                    | 5 (2101 - 2105)                   |
| G2: Low-dose group | 0.25                           | 5 (1201 - 1205)                    | 5 (2201 - 2205)                   |
| G3: Mid-dose group | 0.5                             | 5 (1301 - 1305)                    | 5 (2301 - 2305)                   |
| G4: High-dose group | 1.0                             | 5 (1401 - 1405)                    | 5 (2401 - 2405)                   |
A blood sample of about 1 mL was analyzed by using an automatic hematology analyzer (AD-VIA 120, SIEMEMS, Germany). A blood sample of about 2 mL was centrifuged for the blood coagulation test (3,000 rpm, 10 minutes). The results were measured by using an Automated Coagulation Analyzer (Coapresta 2000, SEKI-SUI, Japan). The blood obtained from the abdominal aorta was analyzed in the blood biochemical test. The results were measured by using an Automatic Analyzer (7180, HITACHI, Japan) and Electrolyte Analyzer (AVL9181, Roche, Germany). Finally, for all animals, the organs and tissues of the body were visually inspected and microscopically observed.

The weights and the hematologic examination and blood chemical test results obtained from the experiments were analyzed by using statistical analysis system (SAS, version 9.3, SAS Institute Inc., U.S.A.). A Bartlett test was conducted to assess the homogeneity of the variance and the significance. The one way analysis of variance (ANOVA) test was carried out when the homogeneity of the variance was recognized, and the Kruskal-Wallis test was conducted post-hoc.

### 3. Results

In this study, no deaths or abnormalities occurred in any of the groups (Tables 2, 3). In addition, no changes in weight were observed in any of the groups (Table 4). Finally, no remarkable changes were observed on the hematologic examination, the blood chemical test, the necropsy or the histopathological examination (Tables 5, 6, 7, 8).

#### Table 2  Summary of mortalities

| Group             | Dose (mL/animal) | Mortality (dead/tested) |   |   |
|-------------------|------------------|-------------------------|---|---|
|                   |                  | Male          | Female |   |
| G1: Control group | 0                | 0%           | 0%     |   |
| G2: Low-dose group| 0.25             | 0%           | 0%     |   |
| G3: Mid-dose group| 0.5              | 0%           | 0%     |   |
| G4: High-dose group| 1.0              | 0%           | 0%     |   |

#### Table 3  Summary of clinical signs

| Group             | Dose (mL/animal) | Sex     | Number of animals | Clinical signs |
|-------------------|------------------|---------|-------------------|---------------|
|                   |                  | Male    | Female | 5 | 5 | NOA |
| G1: Control group | 0                | Male    | Female | 5 | 5 | NOA |
| G2: Low-dose group| 0.25             | Male    | Female | 5 | 5 | NOA |
| G3: Mid-dose group| 0.5              | Male    | Female | 5 | 5 | NOA |
| G4: High-dose group| 1.0              | Male    | Female | 5 | 5 | NOA |

NOA, no observable abnormality.
Table 4  Mean body weights

| Group | Dose (mL/animal) | Sex     | Days after administration | Mean | S.D. | N  |
|-------|-----------------|---------|---------------------------|------|------|----|
|       |                 |         | 0            | 3    | 7    | 14 |
| G1    | 0               | Male    | Mean          | 185.1| 210.7| 247.7| 304.8|
|       |                 | S.D.    | 4.0           | 6.3  | 7.2  | 10.7|
|       |                 | N       | 5             | 5    | 5    | 5   |
|       |                 | Female  | Mean          | 163.7| 178.0| 196.6| 226.2|
|       |                 | S.D.    | 5.8           | 6.1  | 10.1 | 7.3 |
|       |                 | N       | 5             | 5    | 5    | 5   |
| G2    | 0.25            | Male    | Mean          | 184.7| 209.4| 246.5| 304.0|
|       |                 | S.D.    | 4.7           | 9.9  | 12.4 | 19.2|
|       |                 | N       | 5             | 5    | 5    | 5   |
|       |                 | Female  | Mean          | 163.5| 181.1| 200.5| 223.9|
|       |                 | S.D.    | 8.6           | 10.3 | 13.1 | 16.8|
|       |                 | N       | 5             | 5    | 5    | 5   |
| G3    | 0.5             | Male    | Mean          | 184.7| 209.4| 246.5| 304.0|
|       |                 | S.D.    | 4.9           | 6.4  | 6.4  | 11.0|
|       |                 | N       | 5             | 5    | 5    | 5   |
|       |                 | Female  | Mean          | 164.4| 176.2| 192.7| 216.8|
|       |                 | S.D.    | 9.0           | 7.9  | 12.8 | 17.6|
|       |                 | N       | 5             | 5    | 5    | 5   |
| G4    | 1.0             | Male    | Mean          | 184.4| 208.4| 242.3| 291.7|
|       |                 | S.D.    | 6.9           | 11.1 | 10.9 | 11.2|
|       |                 | N       | 5             | 5    | 5    | 5   |
|       |                 | Female  | Mean          | 162.8| 176.9| 194.5| 218.2|
|       |                 | S.D.    | 7.3           | 3.8  | 5.4  | 8.0 |
|       |                 | N       | 5             | 5    | 5    | 5   |

S.D., standard deviation; N, number of animals.

Table 5  Mean hematology parameters

| Group | Dose (mL/animal) | Sex     | Mean RBC (× 10^6 cells/μL) | Mean HGB (g/dL) | Mean HCT (%) | Mean MCV (fL) | Mean MCH (pg) | Mean MCHC (g/dL) | Mean PLT (× 10^3 cells/μL) | Reti (%) |
|-------|-----------------|---------|-----------------------------|-----------------|---------------|---------------|---------------|-----------------|----------------------------|-----------|
| G1    | 0               | Male    | Mean                        | 7.13            | 14.5          | 40.3          | 56.6          | 20.3            | 35.9                      | 1153      | 5.91  |
|       |                 | S.D.    | 0.29                        | 0.3             | 1.5           | 1.8           | 1.0           | 1.1             | 107                       | 2.12      |
|       |                 | N       | 5                          | 5               | 5            | 5             | 5             | 5               | 5                         |           |
|       |                 | Mean    | 7.22                        | 14.8            | 40.3          | 55.9          | 20.5          | 36.7            | 1141                      | 2.37      |
|       |                 | Female  | Mean                        | 0.43            | 0.6           | 1.6           | 1.2           | 0.4             | 0.2                       | 95        | 0.42  |
|       |                 | S.D.    | 0.63                        | 0.6             | 1.6           | 1.2           | 0.4           | 0.2             | 95                        | 0.42      |
|       |                 | N       | 5                          | 5               | 5            | 5             | 5             | 5               | 5                         |           |

(continued)
| Group | Dose (mL/animal) | Sex | Mean | S.D. | N | WBC (× 10^3 cells/μL) | NEU | LYM | MONO | EOS | BASO | PT (sec) | APTT (sec) |
|-------|-----------------|-----|------|------|---|----------------------|-----|-----|------|-----|------|----------|-----------|
| G1    | 0               | Male| Mean | 8.88 |    | 15.0                 | 82.0| 1.8 | 0.5  | 0.2 | 0.2  | 17.6     | 13.9      |
|       |                 |     | S.D. | 3.77 |    | 4.1                  | 3.8 | 0.5 | 0.1  | 0.1 | 0.7  | 0.6      | 0.6       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |
|       |                 | Female| Mean | 6.11 |    | 13.1                 | 82.9| 2.2 | 0.9  | 0.2 | 0.2  | 18.5     | 13.6      |
|       |                 |     | S.D. | 3.73 |    | 4.0                  | 4.8 | 0.9 | 0.4  | 0.0 | 0.4  | 1.4      | 1.4       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |
| G2    | 0.25            | Male| Mean | 8.17 |    | 13.4                 | 83.5| 1.7 | 0.5  | 0.1 | 0.1  | 17.4     | 14.8      |
|       |                 |     | S.D. | 1.14 |    | 3.4                  | 2.8 | 0.3 | 0.0  | 0.1 | 0.4  | 0.3      | 0.3       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |
|       |                 | Female| Mean | 5.42 |    | 16.4                 | 80.2| 1.7 | 1.0  | 0.2 | 0.2  | 18.4     | 13.6      |
|       |                 |     | S.D. | 1.31 |    | 2.8                  | 2.5 | 0.6 | 0.3  | 0.1 | 0.2  | 0.7      | 0.7       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |
| G3    | 0.5             | Male| Mean | 8.36 |    | 16.1                 | 81.1| 1.3 | 0.6  | 0.2 | 0.2  | 17.3     | 14.1      |
|       |                 |     | S.D. | 1.74 |    | 6.1                  | 5.9 | 0.2 | 0.2  | 0.1 | 0.2  | 0.4      | 0.4       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |
|       |                 | Female| Mean | 5.93 |    | 13.3                 | 83.4| 1.3 | 1.1  | 0.2 | 0.2  | 18.1     | 14.2      |
|       |                 |     | S.D. | 1.75 |    | 4.0                  | 4.2 | 0.3 | 0.6  | 0.1 | 0.7  | 1.5      | 1.5       |
|       |                 |     | N    | 5    | 5  | 5                    | 5   | 5   | 5    | 5   | 5    | 5        | 5         |

(continued)
| Group | Dose (mL/animal) | Sex | Mean S.D. N | ALT (U/L) | AST (U/L) | ALP (U/L) | GGT (U/L) | Glu (mg/dL) | BUN (mg/dL) | Crea (mg/dL) | T-Bili (mg/dL) | T-Chol (mg/dL) |
|-------|-----------------|-----|-------------|-----------|-----------|-----------|-----------|-------------|-------------|--------------|---------------|---------------|
| G1    | 0               | Male| Mean 25.9 S.D. 2.3 N 5 | 90.4 | 725.8 | 0.39 | 106 | 10.8 | 0.40 | 66 |
|       |                 |     | Female Mean 22.7 S.D. 2.8 N 5 | 106.8 | 484.6 | 0.52 | 112 | 12.2 | 0.44 | 82 |
| G2    | 0.25            | Male| Mean 27.6 S.D. 4.5 N 5 | 84.4 | 703.3 | 0.38 | 115 | 11.7 | 0.39 | 0.06 | 66 |
|       |                 |     | Female Mean 22.7 S.D. 3.3 N 5 | 87.7 | 544.3 | 0.67 | 109 | 12.9 | 0.46 | 0.08 | 78 |
| G3    | 0.5             | Male| Mean 28.1 S.D. 2.8 N 5 | 83.6 | 808.0 | 0.46 | 111 | 11.0 | 0.40 | 0.06 | 74 |
|       |                 |     | Female Mean 23.5 S.D. 5.2 N 5 | 88.5 | 591.0 | 0.65 | 108 | 12.9 | 0.47 | 0.04 | 70 |
| G4    | 1.0             | Male| Mean 27.1 S.D. 3.8 N 5 | 100.7 | 796.7 | 0.37 | 125 | 10.5 | 0.40 | 0.02 | 66 |
|       |                 |     | Female Mean 20.9 S.D. 3.7 N 5 | 86.5 | 427.2 | 0.46 | 114 | 11.4 | 0.45 | 0.03 | 71 |

Significantly different from the control by Dunnett’s t-test: *P < 0.05. S.D., standard deviation; N, number of animals; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular cell volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular cell hemoglobin concentration; PLT, platelet; Reti, reticulocytes; WBC, white blood cell; NEU, neutrophils; LYM, lymphocytes; MONO, monocytes; EOS, Eosinophils; BASO, basophils; PT, prothrombin time; APTT, active partial thromboplastin time.

Table 6 Mean clinical chemistry
Table 7 Summary of necropsy findings

| Findings | Group | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
|----------|-------|------|--------|------|--------|------|--------|------|--------|------|--------|
| Number of rats examined | G1 (0 mL/animal) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Unremarkable findings | | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
4. Discussion

Eun-Bi San pharmacopuncture has been widely utilized in clinics. In spite of this, no clinical reviews on the effects of Eun-Bi San pharmacopuncture have been published, but there have been many studies on the component herbs of this pharmacopuncture have been published. Pharmacopuncture of Angelicae gigantis radix, which is a component of Eun-Bi San pharmacopuncture, has an anti-inflammatory property related to its inhibition of nitric oxide (NO) and prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS) induced macrophages, so it may have a therapeutic potential for the treatment of various inflammatory diseases [5]. Angelicae gigantis radix pharmacopuncture also has inhibitory effect on elastase activity as well as an antioxidant effect on NO and 1,1-diphenyl-2-picrylhydrazyl (DPPH) [6]. Angelicae gigantis radix pharmacopuncture has an anti-inflammatory effect related with its inhibition of pro-inflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), granulocyte colony stimulating factor (G-CSF), Granulocyte macrophage-colony stimulating factor (GM-CSF), and macrophage inflammatory protein-1α (MIP-1α) in LPS induced macrophages [7]. Strychni semen pharmacopuncture inserted into ST36 is thought to have an effect on adjuvant arthritis in rats [8]. Finally, Glycyrrhizae radix pharmacopuncture is beneficial in the inhibition of allergic inflammatory responses and has an anti-inflammation effect [9, 10].

Thus, the component herbs of Eun-Bi San pharmacopuncture have been reported to have many effects on several disorders. Although it is used in clinics, safety studies on Eun-Bi San pharmacopuncture are insufficient, so more safety studies are needed. The toxicity study is an essential data base and is important for evaluating the safety of test substances in medications [11].

This study was carried out to provide objective safety data for Eun-Bi San pharmacopuncture. Doses of 0.25, 0.5 and 1.0 mL of Eun-Bi San pharmacopuncture were administered to the experimental groups, and a 1.0-mL dose of normal saline solution was administered to the control group. No deaths occurred, and no abnormalities were found in any of the four groups. No significant changes in the clinical signs, weights, hematologic examination results and blood chemical test results were observed; all results were within normal ranges. When the rats were dissected to check for abnormalities in organs and tissue, no significant histopathological findings were suggested. To analyze the toxicity of Eun-Bi San pharmacopuncture, we need more study on its acute and chronic harmful effects and its relations with capacity reaction. Animal testing is the ultimate and basic way to conduct safety assessments [12]. The Korea Food & Drug Administration has testing protocol guidelines for the study of toxicity, and all experiments should be carried out following GLP regulations [13].

The results showed that treatment with 1.0-mL/animal of Eun-Bi San pharmacopuncture produced no changes in weight or in the results of hematological, blood chemical, and autopsy examinations. Because Eun-Bi San pharmacopuncture had no risks associated with its use in this study, Eun-Bi San pharmacopuncture administration can be considered to be a safe treatment; however, additional study is needed to confirm this result.

5. Conclusion

The results suggest that an intramuscular injection of 1.0-mL/animal of Eun-Bi San pharmacopuncture did not cause any changes in weight or in the results of hematological, blood chemical, and necropsy examinations. It also did not result in any mortalities. These results indicates that Eun-Bi San pharmacopuncture intramuscular injection can be used as a safe treatment.

Acknowledgment

This paper was supported by wonkwang university in 2013.

Conflict of interest

The authors declare that there are no conflict of interest.
References

1. Korean Pharmacopuncture Institute. [Pharmacopunctureology principles and clinical applications]. Seoul: Elsevier Korea; 2012. p. 3-4. Korean.
2. Joo HJ. [Researches on pharmacopuncture]. KIOM. 1995;5:193-210. Korean.
3. Seo BI, Roh SS. [A philological study on poisoning of Areca semen]. The Journal of Jeahan Oriental Medical Academy. 2012;10(1):119-25. Korean.
4. Kang TG. Antimicrobial effect and cytotoxicity of Glycyrrhizae radix [master’s thesis]. [Gangwon]: Sangji university. 2008.
5. Choi YJ, Roh JD. [Effects of Angelicae gigantis radix pharmacopuncture on nitric oxide and prostaglandin E2 production in macrophage]. J Pharmacopuncture. 2011;14(3):81-90. Korean.
6. Lee SM, Lim SC, Lee YK, Kim JS. [Effects of Angelica gigantis pharmacopuncture extracts on the elastase activity and DPPH and NO scavenging activities]. The acupuncture. 2011;28(6):35-42. Korean.
7. Han HS. [Anti-inflammatory effect of Angelicae acutilobae radix water extract on LPS-stimulated mouse macrophages]. Kor J Herbology. 2013;28(6):129-33. Korean.
8. Bae CW, Kim KH, Hwang HS, Kim YS. [Effects of Strychni semen aqua-acupuncture in rats with arthritis induced by Freund’s complete adjuvant]. The acupuncture. 2001;18(1):217-25. Korean.
9. Lee HD, Song CH. [Effect of glycyrrhizae radix pharmacopuncture on PCA and secretion of β-hexosaminidase and cytokines in RBL-2H3 cells]. Korean J Acupunct. 2011;28(3):73-83. Korean.
10. Bak JP, Son JH, Kim YM, Lee EY, Leem KH, Kim EH. [Suppression of inflammatory macrophage responses by glycyrrhiza uralensis herbal acupuncture extract]. Korean J Acupunct. 2011;28(4):49-58. Korean.
11. Kim YK. [The principle and test method. Toxicology]. Seoul: Donghwagisul; 1994(3). p. 15-8. Korean.
12. Kim YG. [Toxicology]. Seoul: Donghwagisul; 1984. p. 15-8. Korean.
13. Korea Food & Drug Administration. Korea Food & Drug Administration notification [Internet]. Seoul: Korea Food & Drug Administration; 2005 [cited 2013 Mar 1]. Available from: http://lawwizice.wordpress.com/.